Full TitleA Phase I Multiple Ascending Dose Study of DS-3201B in Subjects with Lymphomas
The purpose of this study is to assess the safety and effectiveness of the investigational drug DS-3201b in people with T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL) that came back or continues to grow despite prior treatment. DS-3201b may work by blocking the activity of two proteins called EZH1 and EZH2, which are involved in cancer growth. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have ATL or PTCL that came back or continues to grow despite prior treatment.
- Patients should recover from the serious side effects of previous therapies before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Steven Horwitz at 646-608-3725.